Personalis Inc (PSNL)

Jan 13, 2025, 5:00 AM EST - 4 days ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 10 days ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 4 weeks ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 4 weeks ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 2 months ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 2 months ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 2 months ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 2 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 3 months ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 4 months ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 19, 2024, 4:05 PM EDT - 5 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 18, 2024, 7:47 AM EDT - 5 months ago

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 16, 2024, 8:30 AM EDT - 5 months ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Aug 7, 2024, 11:09 PM EDT - 5 months ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 5 months ago

Personalis Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:01 PM EDT - 6 months ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 24, 2024, 4:01 PM EDT - 6 months ago

Personalis to Announce Second Quarter 2024 Financial Results

Jun 18, 2024, 4:01 PM EDT - 7 months ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Jun 13, 2024, 8:00 AM EDT - 7 months ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Jun 4, 2024, 4:05 PM EDT - 8 months ago

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

May 31, 2024, 9:05 AM EDT - 8 months ago

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

May 22, 2024, 9:05 AM EDT - 8 months ago

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

May 22, 2024, 9:00 AM EDT - 8 months ago

Antares Bolsters Private Wealth Team with Three New Senior Appointments

KHC

May 8, 2024, 11:53 PM EDT - 9 months ago

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 9 months ago

Personalis Reports First Quarter 2024 Financial Results

Apr 24, 2024, 4:01 PM EDT - 9 months ago

Personalis to Announce First Quarter 2024 Financial Results

Mar 28, 2024, 4:01 PM EDT - 10 months ago

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 9:00 AM EDT - 10 months ago

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 26, 2024, 9:00 AM EDT - 10 months ago

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Feb 28, 2024, 9:20 PM EST - 11 months ago

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 11 months ago

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Jan 30, 2024, 9:00 AM EST - 1 year ago

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Jan 16, 2024, 9:05 AM EST - 1 year ago

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Jan 5, 2024, 9:05 AM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Dec 4, 2023, 9:15 AM EST - 1 year ago

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Nov 28, 2023, 4:15 PM EST - 1 year ago

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Nov 7, 2023, 11:04 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 8:15 AM EDT - 1 year ago

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Oct 24, 2023, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2023 Financial Results

Oct 21, 2023, 4:25 AM EDT - 1 year ago

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Oct 19, 2023, 7:15 AM EDT - 1 year ago

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

Oct 18, 2023, 7:15 AM EDT - 1 year ago

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Sep 6, 2023, 8:27 AM EDT - 1 year ago

Personalis: Collaborations Should Ignite Growth Narrative

Aug 29, 2023, 4:01 PM EDT - 1 year ago

Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 8, 2023, 11:24 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2023 Financial Results

Jul 25, 2023, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2023 Financial Results

Jun 26, 2023, 5:00 PM EDT - 1 year ago

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics